Exelixis | EXEL - Selling And Administration Expenses


Exelixis reported $123.02M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 4.05B 647M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Genmab DKK 208M 60M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025